Medullary thyroid carcinoma

Current Treatment Options in Oncology

Volumn 4, Issue 4, 2003, Pages 339-347

  Moley, Jeffrey F ^a  

^a USA   (United States)

Author keywords

Calcitonin Level; Lanreotide; Medullary Thyroid Cancer; Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type

Indexed keywords

ARTICLE; HUMAN; MEDULLARY CARCINOMA; THYROID TUMOR;

CARCINOMA, MEDULLARY; HUMANS; THYROID NEOPLASMS;

EID: 0642274208     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0009-8     Document Type: Article

References (49)

1. Moley JF, DeBenedetti MK: Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880–887. This paper discusses the nodal drainage of the thyroid and the findings in regional nodes in a large series of patients who had removal of central and bilateral nodes (levels I-V) in operations for MTC. The paper provides guidelines for the extent of resection. DOI: 10.1097/00000658-199906000-00016
2. Moley JF, Lairmore TC, Phay JE: Hereditary endocrinopathies. Curr Probl Surg 1999, 36:653–762. DOI: 10.1016/S0011-3840(99)80001-X
3. Mulligan L, Kwok J, Healy C: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 1993, 363:458–460. DOI: 10.1038/363458a0
4. Donis-Keller H, Dous S, Chi D, et al.: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851–856. DOI: 10.1093/hmg/2.7.851
5. Cohen MS, Phay JE, Albinson C, et al.: Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002, 235:648–654. DOI: 10.1097/00000658-200205000-00006
6. O’Riordain DS, O’Brien T, Crotty TB, et al.: Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995, 118:936–942. DOI: 10.1016/S0039-6060(05)80097-2
7. Gagel RF, Tashjian AH Jr, Cummings T, et al.: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A, an 18 year experience. N Engl J Med 1988, 318:478–484. DOI: 10.1056/NEJM198802253180804
8. Wells SA Jr, Chi DD, Toshima K, et al.: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994, 220:237–247. DOI: 10.1097/00000658-199409000-00002
9. Lips CJ, Landsvater RM, Hoppener JW, et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828–835. DOI: 10.1056/NEJM199409293311302
10. Sizemore GW, Heath H, Carney JA: Multiple endocrine neoplasia type 2. Clin Endocrinol Metab 1980, 9:299–315.
11. Dralle H, Gimm O, Simon D, et al.: Prophylactic thyroidectomy in 75 children with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998, 22:744–751. DOI: 10.1007/s002689900463
12. Dralle H: Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002, 89:1073–1075. This report describes this author’s extensive personal experience with cervical and mediastinal operations for MTC. DOI: 10.1046/j.1365-2168.2002.02160.x
13. Weber T, Schilling T, Frank-Raue K, et al.: Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001, 130:1044–1049. This paper describes the approach to MTC from a large American cancer center. DOI: 10.1067/msy.2001.118380a
14. Dralle H, Damm I, Scheumann GF, et al.: Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994, 24:112–121. DOI: 10.1007/BF02473391
15. Decker RA, Geiger JD, Cox CE, et al.: Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 1996, 20:814–820. DOI: 10.1007/s002689900124
16. Russell CF, van Heerden JA, Sizemore GW, et al.: The surgical management of medullary carcinoma. Ann Surg 1983, 197:42–48.
17. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr: Parathyroid autotransplantation during thyroidectomy: results of long-term follow-up. Ann Surg 1996, 223:472–477. DOI: 10.1097/00000658-199605000-00003
18. Wells SA, Ross AJ, Dale JK, Gray RS: Transplantation of the parathyroid glands: current status. Surg Clin North Am 1979, 59:167–177.
19. Wells SA Jr, Skinner MA: Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998, 106:29–34.
20. Block MA, Jackson CE, Greenwalk KA, et al.: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980, 115:142–148.
21. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC: Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 1979, 43:825–837. DOI: 10.1002/1097-0142(197903)43:3<825::AID-CNCR2820430308>3.0.CO;2-Q
22. van Heerden JA, Grant CS, Gharib H, et al.: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990, 212:395–401. This paper describes the long-term outcome in a group of patients with elevated calcitonin levels after surgery and provides a rationale for observation rather than aggressive treatment of this problem. DOI: 10.1097/00000658-199010000-00002
23. Normann T, Gautvik KM, Johannessen JV, Brennhovd IO: Medullary carcinoma of the thyroid in Norway. Acta Endocrinol 1976, 83:71–85.
24. O’Riordain DS, O’Brien T, Weaver AL, et al.: Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994, 116:1017–1023.
25. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995, 118:1024–1029. This paper describes the success of diagnostic laparoscopy and liver evaluation in localizing occult metastatic disease in patients with elevated calcitonin levels after treatment of MTC. DOI: 10.1016/S0039-6060(05)80109-6
26. Cohen MS, DeBenedetti M, Moley JF: Laparoscopic liver evaluation for recurrent medullary thyroid carcinoma. Paper presented at the Annual Meeting of the Society of Surgical Oncology. Los Angeles, CA; 2003.
27. Norton J, Doppman J, Brennan M: Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980, 87:616–622.
28. Block M, Jackson C, Tashjian A: Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations. Arch Surg 1992, 113:368–372.
29. Buhr H, Kallinowski F, Raue F, et al.: Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma: three year results. Cancer 1993, 72:3685–3693. DOI: 10.1002/1097-0142(19931215)72:12<3685::AID-CNCR2820721221>3.0.CO;2-3
30. Tisell L, Hansson G, Jansson S, Salander H: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986, 99:60–66.
31. Moley JF, Wells SA, Dilley WG, Tisell LE: Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993, 114:1090–1095.
32. Moley J, Dilley W, DeBenedetti M: Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997, 225:734–743. This paper describes the author’s initial personal experience with reoperation for MTC. DOI: 10.1097/00000658-199706000-00011
33. Husain M, Alsever RN, Lock JP, et al.: Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 1978, 9:22–25. DOI: 10.1159/000178893
34. Scherubl H, Raue F, Ziegler R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer: phase II study. J Cancer Res Clin Oncol 1990, 116:21–23. DOI: 10.1007/BF01612635
35. Orlandi F, Caraci P, Berruti A, et al.: Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994, 5:763–765.
36. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE: Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FUstreptozocin and 5 FU-dacarbazine. Br J Cancer 1995, 71:363–365. This paper summarizes the authors’ experience with chemotherapy for MTC. There are few responses and many patients with stable disease, but many patients will have stable disease even if nothing is done [22].
37. Grohn P, Kumpulainen E, Jakobsson M: Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol 1990, 29:950–951.
38. Juweid ME, Hajjar G, Stein R, et al.: Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000, 41:93–103.
39. Schott M, Feldkamp J, Klucken M, et al.: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002, 51:663–668. DOI: 10.1007/s00262-002-0325-z
40. Mahler C, Verheist J, Delouneville M, et al.: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 1990, 33:261.
41. Smid WM, Dullaart RP: Octreotide for medullary thyroid carcinoma associated diarrhea. Neth J Med, 1992. 40:240–243.
42. Vitale G, Tagliaferri P, Caraglia M, et al.: Slow release lanreotide in combination with interferon-alpha 2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:983–988. DOI: 10.1210/jc.85.3.983
43. Cohen MS, Hussain HB, Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002, 132:960–966. DOI: 10.1067/msy.2002.128562
44. Carlomagno F, Vitagliano D, Guida T, et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284–7290.
45. Carlomagno F, Vitagliano D, Guida T, et al.: The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002, 62:1077–1082.
46. Saad M, Guido J, Samaan N: Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983, 57:124–128. DOI: 10.1210/jcem-57-1-124
47. Brierley JD, Tsang RW: External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 1996, 25:141–157. This review summarizes the radiation therapy experience in MTC. DOI: 10.1016/S0889-8529(05)70316-9
48. Nguyen T, Chassard JL, Lagarde P, et al.: Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes—the Radiotherapy Cooperative Group. Radiother Oncol 1992, 23:1–5. DOI: 10.1016/0167-8140(92)90298-9
49. Samaan NA, Schultz PN, Hickey RC: Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res Suppl 1989, 21:21–25.